相关实验视频

Updated: Jun 28, 2025

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

聚二甲基西洛素有机-无机复合药物储与糖化物

Ahmed Gedawy^1,2, Hani Al-Salami^1,2, Crispin R Dass^1,2

¹Curtin Medical School, Curtin University, Bentley 6102, Australia.

International journal of molecular sciences

|April 13, 2024

概括

一个新的复合珠子有效地使用离子凝过程封装了gliclazide. 这种优化的药物输送系统显示了对骨肌肉应用的受控释放和生物相容性.

科学领域:

材料科学材料科学材料科学
制药科学制药科学
生物材料工程生物材料工程

背景情况:

糖尿病管理需要有效的药物输送系统.
格利克拉是广泛使用的口服低血糖剂.
开发先进的药物载体对于改善治疗结果至关重要.

研究的目的:

开发和优化一种新的有机-无机复合珠子,用于克拉的输送.
研究开发系统的封装效率和药物释放动力学.
为了评估复合珠子对潜在的骨肌肉药物输送的生物相容性.

主要方法:

离子凝工艺使用奇托,四甲基酸盐 (TEOS) 和酸.
聚二甲基酸盐 (PDMS) 与TEOS的交叉连接,然后对Na-alginate进行接种.
药物配方 ("G op") 的优化,使用3^2因子设计和响应表面方法.
对封装效率 (EE%) 和8小时药物释放率 (% DR 8小时) 的分析.
动力建模 (Korsmeyer-Peppas) 和C2C12神经细胞的体外细胞活力测试.

主要成果:

优化的配方 ("G op") 实现了高封装效率 (93.48% ± 0.19) 和受控的药物释放 (70.29% ± 0.18 8小时).
甘胺的释放遵循科尔斯迈耶-佩帕斯模型 (R^2 = 0.95),表明超级案例II运输.
复合珠子表现出依赖pH的胀和与C2C12核细胞 (92.17%±1.18细胞活力) 的良好生物相容性.

结论:

一种新型的,生物相容的有机-无机复合珠子已成功开发用于克拉的输送.
优化的系统提供了可控的药物释放,并显示了骨肌肉药物输送应用的前景.
这种生物材料平台为先进的制药配方提供了基础.

关键词:

在PDMS中使用PDMS.基多酸盐的使用方法复合珠子珠子的组成糖化的使用方法骨髓质细胞细胞质细胞质细胞质细胞质细胞质细胞质细胞质.这是骨肌肉的骨架肌肉.

更多相关视频

Synthesis of Thermogelling PolyN-isopropylacrylamide-graft-chondroitin Sulfate Composites with Alginate Microparticles for Tissue Engineering

Synthesis of Thermogelling PolyN-isopropylacrylamide-graft-chondroitin Sulfate Composites with Alginate Microparticles for Tissue Engineering

Published on: October 26, 2016

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

相关概念视频

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...